Company

MBX Biosciences, Inc.

MBX Biosciences develops Precision Endocrine Peptide (PEP) therapeutics aimed at endocrine and metabolic disorders.

About

Founded in 2019 and based in Carmel, US, MBX Biosciences, Inc. develops PEP therapeutic candidates for endocrine and metabolic disorders, including hypoparathyroidism and diabetes. Kent Hawryluk is CEO. The company raised USD 63.50 mn in a Series C round led by Deep Track Capital on September 12, 2024, and then raised USD 163.20 mn in an IPO by selling 10.2 million shares at USD 16 each on the Nasdaq Global Select Market under the ticker MBX. Its current valuation is USD 278.08 mn.

4Funding rounds

11Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in